Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Entry into Material Definitive Agreement
BIIB logo

Biogen Completes $5.3 Billion Acquisition of Apellis to Drive Growth Through 2030

BIIB8-KFiling Date: 5/14/2026
Biogen Inc.
Description

What this story covers

Biogen finalized its $5.3 billion acquisition of Apellis Pharmaceuticals, adding two FDA-approved rare disease treatments. The deal, funded by cash and a $2 billion loan, aims to diversify revenue and boost earnings per share starting in 2027.

Story snapshot

CompanyBiogen Inc.
TickerBIIB
VariantStandard detailed
Duration5:18
Filing type8-K
PeriodN/A
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-222908
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in